Amendment: SEC Form SC 13G/A filed by LifeStance Health Group Inc.

$LFST
Medical/Nursing Services
Health Care
Get the next $LFST alert in real time by email
SC 13G/A 1 d899837dsc13ga.htm SC 13G/A SC 13G/A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)*

 

 

LifeStance Health Group, Inc.

(Name of Issuer)

Common Stock, par value $0.01 per share

(Title of Class of Securities)

53228F101

(CUSIP Number)

September 30, 2024

(Date of Event Which Requires Filing of this Statement)

 

 

Check the Appropriate Box to Designate the Rule Pursuant to Which this Schedule Is Filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 


 1.   

 Names of Reporting Persons

 

Summit Partners, L.P.

 2.  

 Check The Appropriate Box if a Member of a Group (See Instructions)

 (a) ☐  (b) ☐

 

 3.  

 SEC Use Only

 

 4.  

 Citizenship or Place of Organization

 

Delaware

Number of

Shares  Beneficially 

Owned By

Each

Reporting

Person

With

   5.   

 Sole Voting Power

 

0

   6.  

 Shared Voting Power

 

41,932,358

   7.  

 Sole Dispositive Power

 

0

   8.  

 Shared Dispositive Power

 

41,932,358

 9.   

 Aggregate Amount Beneficially Owned by Each Reporting Person

 

 41,932,358

10.  

 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

 

 ☐

11.  

 Percent of Class Represented By Amount in Row (9)

 

10.96%(1)

12.  

 Type of Reporting Person (See Instructions)

 

PN

 

(1)

Calculated based on 382,622,704 shares of common stock, par value $0.01 per share (“Common Stock”) outstanding as of July 31, 2024, as reported on the Issuer’s Form 10-Q, filed on August 8, 2024.


 1.   

 Names of Reporting Persons

 

 Summit Partners Growth Equity Fund IX-A, L.P.

 2.  

 Check The Appropriate Box if a Member of a Group (See Instructions)

 (a) ☐  (b) ☐

 

 3.  

 SEC Use Only

 

 4.  

 Citizenship or Place of Organization

 

Delaware

Number of

Shares  Beneficially 

Owned By

Each

Reporting

Person

With

   5.   

 Sole Voting Power

 

0

   6.  

 Shared Voting Power

 

 25,677,643

   7.  

 Sole Dispositive Power

 

0

   8.  

 Shared Dispositive Power

 

 25,677,643

 9.   

 Aggregate Amount Beneficially Owned by Each Reporting Person

 

 25,677,643

10.  

 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

 

 ☐

11.  

 Percent of Class Represented By Amount in Row (9)

 

 6.71%(1)

12.  

 Type of Reporting Person (See Instructions)

 

PN

 

(1)

Calculated based on 382,622,704 shares of Common Stock as of July 31, 2024, as reported on the Issuer’s Form 10-Q, filed on August 8, 2024.


 1.   

 Names of Reporting Persons

 

 Summit Partners Growth Equity Fund IX-B, L.P.

 2.  

 Check The Appropriate Box if a Member of a Group (See Instructions)

 (a) ☐  (b) ☐

 

 3.  

 SEC Use Only

 

 4.  

 Citizenship or Place of Organization

 

Delaware

Number of

Shares  Beneficially 

Owned By

Each

Reporting

Person

With

   5.   

 Sole Voting Power

 

0

   6.  

 Shared Voting Power

 

 16,032,765

   7.  

 Sole Dispositive Power

 

0

   8.  

 Shared Dispositive Power

 

 16,032,765

 9.   

 Aggregate Amount Beneficially Owned by Each Reporting Person

 

 16,032,765

10.  

 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

 

 ☐

11.  

 Percent of Class Represented By Amount in Row (9)

 

 4.19%(1)

12.  

 Type of Reporting Person (See Instructions)

 

PN

 

(1)

Calculated based on 382,622,704 shares of Common Stock as of July 31, 2024, as reported on the Issuer’s Form 10-Q, filed on August 8, 2024.


 1.   

 Names of Reporting Persons

 

 Summit Investors GE IX/VC IV (UK), L.P.

 2.  

 Check The Appropriate Box if a Member of a Group (See Instructions)

 (a) ☐  (b) ☐

 

 3.  

 SEC Use Only

 

 4.  

 Citizenship or Place of Organization

 

 Cayman Islands

Number of

Shares  Beneficially 

Owned By

Each

Reporting

Person

With

   5.   

 Sole Voting Power

 

0

   6.  

 Shared Voting Power

 

 18,750

   7.  

 Sole Dispositive Power

 

0

   8.  

 Shared Dispositive Power

 

 18,750

 9.   

 Aggregate Amount Beneficially Owned by Each Reporting Person

 

 18,750

10.  

 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

 

 ☐

11.  

 Percent of Class Represented By Amount in Row (9)

 

 0.01%(1)

12.  

 Type of Reporting Person (See Instructions)

 

PN

 

(1)

Calculated based on 382,622,704 shares of Common Stock as of July 31, 2024, as reported on the Issuer’s Form 10-Q, filed on August 8, 2024.


 1.   

 Names of Reporting Persons

 

 Summit Partners Entrepreneur Advisors Fund II, L.P.

 2.  

 Check The Appropriate Box if a Member of a Group (See Instructions)

 (a) ☐  (b) ☐

 

 3.  

 SEC Use Only

 

 4.  

 Citizenship or Place of Organization

 

 Delaware

Number of

Shares  Beneficially 

Owned By

Each

Reporting

Person

With

   5.   

 Sole Voting Power

 

0

   6.  

 Shared Voting Power

 

 23,961

   7.  

 Sole Dispositive Power

 

0

   8.  

 Shared Dispositive Power

 

 23,961

 9.   

 Aggregate Amount Beneficially Owned by Each Reporting Person

 

 23,961

10.  

 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

 

 ☐

11.  

 Percent of Class Represented By Amount in Row (9)

 

 .01%(1)

12.  

 Type of Reporting Person (See Instructions)

 

PN

 

(1)

Calculated based on 382,622,704 shares of Common Stock as of July 31, 2024, as reported on the Issuer’s Form 10-Q, filed on August 8, 2024.


 1.   

 Names of Reporting Persons

 

 Summit Investors GE IX/VC IV, LLC

 2.  

 Check The Appropriate Box if a Member of a Group (See Instructions)

 (a) ☐  (b) ☐

 

 3.  

 SEC Use Only

 

 4.  

 Citizenship or Place of Organization

 

 Delaware

Number of

Shares  Beneficially 

Owned By

Each

Reporting

Person

With

   5.   

 Sole Voting Power

 

0

   6.  

 Shared Voting Power

 

 179,239

   7.  

 Sole Dispositive Power

 

0

   8.  

 Shared Dispositive Power

 

 179,239

 9.   

 Aggregate Amount Beneficially Owned by Each Reporting Person

 

 179,239

10.  

 Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares

 

 ☐

11.  

 Percent of Class Represented By Amount in Row (9)

 

 0.05%(1)

12.  

 Type of Reporting Person (See Instructions)

 

 OO

 

(1)

Calculated based on 382,622,704 shares of Common Stock as of July 31, 2024, as reported on the Issuer’s Form 10-Q, filed on August 8, 2024.


Item 1(a).

Name of Issuer

LifeStance Health Group, Inc. (the “Issuer”)

 

Item 1(b).

Address of the Issuer’s Principal Executive Offices

4800 N. Scottsdale Road, Suite 6000

Scottsdale, Arizona 85251

 

Item 2(a).

Names of Persons Filing

This statement is filed by the entities and persons listed below, all of whom together are referred to herein as the “Reporting Persons”:

 

  (i)

Summit Partners, L.P.;

 

  (ii)

Summit Partners Growth Equity Fund IX-A, L.P.;

 

  (iii)

Summit Partners Growth Equity Fund IX-B, L.P.;

 

  (iv)

Summit Investors GE IX/VC IV (UK), L.P.;

 

  (v)

Summit Partners Entrepreneur Advisors Fund II, L.P.; and

 

  (vi)

Summit Investors GE IX/VC IV, LLC.

 

Item 2(b).

Address of the Principal Business Office, or if none, Residence:

222 Berkeley Street, 18th Floor

Boston, MA 02116

 

Item 2(c).

Citizenship

See responses to Item 4 on each cover page.

 

Item 2(d).

Title of Class of Securities

Common Stock, par value $0.01 per share

 

Item 2(e).

CUSIP Number

53228F101

 

Item 3.

If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a(n):

Not Applicable.

 

Item 4.

Ownership

 

  (a)

Amount beneficially owned:

See responses to Item 9 on each cover page.

 

  (b)

Percent of Class:

See responses to Item 11 on each cover page.

 

  (c)

Number of shares as to which the Reporting Person has:

 

  (i)

Sole power to vote or to direct the vote:

See responses to Item 5 on each cover page.


  (ii)

Shared power to vote or to direct the vote:

See responses to Item 6 on each cover page.

 

  (iii)

Sole power to dispose or to direct the disposition of:

See responses to Item 7 on each cover page.

 

  (iv)

Shared power to dispose or to direct the disposition of:

See responses to Item 8 on each cover page.

Summit Partners, L.P. is the managing member of Summit Partners GE IX, LLC, which is general partner of Summit Partners GE IX, LP, which is the general partner of Summit Partners Growth Equity Fund IX-A, L.P. and Summit Partners Growth Equity Fund IX-B, L.P. Summit Master Company, LLC is (i) the sole member of Summit Partners Entrepreneur Advisors GP II, LLC, which is the general partner of Summit Partners Entrepreneur Advisors Fund II, L.P. and (ii) the general partner of Summit Partners L.P., which is the manager of Summit Investors Management, LLC, which is the manager of Summit Investors GE IX/VC IV, LLC, and the general partner of Summit Investors GE IX/VC IV (UK), L.P. Summit Master Company, LLC, as the sole member of Summit Partners Entrepreneur Advisors GP II, LLC, the managing member of Summit Investors Management, LLC and general partner of Summit Partners, L.P., has delegated investment decisions, including voting and dispositive power, to Summit Partners, L.P. and its investment committee responsible for voting and investment decisions with respect to the reported securities held by Summit Partners, L.P., through a four-person investment committee. Peter Y. Chung, Darren M. Black, Mark A. deLaar and Craig D. Frances are the current members of the investment committee, and as such may be deemed to have voting and dispositive authority over the reported securities, but each of the foregoing disclaim such beneficial ownership. This Statement shall not be construed as an admission that the Reporting Persons or any of the members of the investment committee are, for the purpose of Section 13(d) or 13(g) of the Exchange Act, the beneficial owner of any securities covered by this Statement.

 

Item 5.

Ownership of Five Percent or Less of a Class

Not Applicable.

 

Item 6.

Ownership of More than Five Percent on Behalf of Another Person

Not Applicable.

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company

Not Applicable.

 

Item 8.

Identification and Classification of Members of the Group

Not Applicable.

 

Item 9.

Notice of Dissolution of Group

Not Applicable.

 

Item 10.

Certification

Not Applicable.


SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: November 8, 2024

 

Summit Partners, L.P.
By:   Summit Master Company, LLC
Its:   General Partner
By:   /s/ Adam H. Hennessey, as POA
  Adam H. Hennessey, as Power of Attorney
Summit Partners Growth Equity Fund IX-A, L.P.
By:   Summit Partners GE IX, LP
Its:   General Partner
By:   /s/ Adam H. Hennessey, as POA
  Adam H. Hennessey, as Power of Attorney
Summit Partners Growth Equity Fund IX-B, L.P.
By:   Summit Partners GE IX, LP
Its:   General Partner
By:   /s/ Adam H. Hennessey, as POA
  Adam H. Hennessey, as Power of Attorney
Summit Investors GE IX/VC IV, LLC
By:   Summit Investors Management, LLC
Its:   Manager
By:   /s/ Adam H. Hennessey, as POA
  Adam H. Hennessey, as Power of Attorney
Summit Investors GE IX/VC IV (UK), L.P.
By:   Summit Investors Management, LLC
Its   Manager
By:   /s/ Adam H. Hennessey, as POA
Adam H. Hennessey, as Power of Attorney
Summit Partners Entrepreneur Advisors Fund II, L.P.
By:   Summit Partners Entrepreneur Advisors GP II, LLC
Its   General Partner
By:   /s/ Adam H. Hennessey, as POA
  Name: Adam H. Hennessey
  Title: Power of Attorney


EXHIBIT LIST

 

Exhibit A    Joint Filing Agreement, dated as of February 4, 2022, incorporated herein by reference to of the statement on Schedule 13G filed by the Reporting Persons on February 4, 2022.
Exhibit B    Powers of Attorney, dated as of October 25, 2021, incorporated herein by reference to of the statement on Schedule 13G filed by the Reporting Persons on February 4, 2022.
Get the next $LFST alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$LFST

DatePrice TargetRatingAnalyst
12/16/2024$10.00Neutral → Buy
Goldman
1/3/2024$7.00Underweight
Barclays
5/15/2023$8.00 → $9.00Outperform → Market Perform
TD Cowen
1/6/2023$8.00Equal-Weight → Overweight
Morgan Stanley
11/7/2022$7.25Buy
Jefferies
3/17/2022$19.00 → $10.00Buy → Neutral
UBS
12/17/2021$15.00 → $10.00Equal-Weight
Morgan Stanley
11/9/2021$24.00 → $12.00Overweight → Neutral
JP Morgan
More analyst ratings

$LFST
Press Releases

Fastest customizable press release news feed in the world

See more
  • LifeStance Appoints Dave Bourdon as CEO; Ken Burdick Named Executive Chairman

    Ryan McGroarty to Become Chief Financial Officer SCOTTSDALE, Ariz., Feb. 27, 2025 /PRNewswire/ -- LifeStance Health Group, Inc. ("LifeStance" or the "Company") (NASDAQ:LFST), one of the nation's largest providers of outpatient mental health care, today announced that its Board of Directors has appointed Dave Bourdon as the Company's new Chief Executive Officer. Bourdon, who joined LifeStance as Chief Financial Officer in 2022, is succeeding Ken Burdick, who is retiring from his role as CEO and will assume the role of Executive Chairman. Bourdon has also been appointed to serve on the Board of Directors. In addition, Ryan McGroarty has been appointed to serve as the company's new Chief Financ

    $LFST
    Medical/Nursing Services
    Health Care
  • LifeStance to Host Fourth Quarter and Full Year 2024 Earnings Conference Call on February 27, 2025

    SCOTTSDALE, Ariz., Feb. 06, 2025 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ:LFST), one of the nation's largest providers of outpatient mental health care, will issue its fourth quarter and full year 2024 earnings release before the market opens on Thursday, February 27, 2025. LifeStance will host a live earnings conference call to discuss fourth quarter and full year results on February 27, 2025, at 8:30 a.m. Eastern Time. To participate in the call, please dial 1-800-715-9871, domestically, or 1-646-307-1963, internationally, and use conference ID 4372752, or ask to be joined into the LifeStance call. A real-time audio webcast can be accessed via the Events and Presentati

    $LFST
    Medical/Nursing Services
    Health Care
  • Zarminali Health Launches with $40M in Seed Funding to Transform Pediatric Care through Nationwide, Multi-specialty Practice Group

    CHICAGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Zarminali Health, the first outpatient pediatric destination purpose-built to provide modern, seamlessly coordinated primary and specialty care nationwide, today announced $40M in seed financing led by General Catalyst. The company will leverage the latest healthcare technology and an integrated approach to both primary and specialty care that alleviates family burdens and revitalizes patient and clinician experiences. This substantial funding, including a venture debt facility, will fuel the company's go-to-market vision and continue to support the opening of its initial locations in fall 2024 and beyond. Pediatric care today is long overdue f

    $LFST
    Medical/Nursing Services
    Health Care

$LFST
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$LFST
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$LFST
SEC Filings

See more

$LFST
Leadership Updates

Live Leadership Updates

See more
  • LifeStance Appoints Dr. Teresa DeLuca to Board of Directors

    SCOTTSDALE, Ariz., March 12, 2024 /PRNewswire/ -- LifeStance Health, one of the nation's largest providers of virtual and in-person outpatient mental healthcare, today announced that Dr. Teresa DeLuca has joined the company's board of directors. Dr. DeLuca is a psychiatrist and accomplished physician executive with over 20 years of leadership experience, having held senior executive leadership roles at Magellan Health, Humana and Walgreens, and brings extensive healthcare operations and clinical management expertise to LifeStance's board of directors. "Dr. DeLuca's background

    $LFST
    Medical/Nursing Services
    Health Care
  • LifeStance Appoints Dr. Ujjwal Ramtekkar as Chief Medical Officer

    SCOTTSDALE, Ariz., Jan. 19, 2024 /PRNewswire/ -- LifeStance Health, one of the nation's largest providers of virtual and in-person outpatient mental healthcare, today announced that Dr. Ujjwal Ramtekkar will join the company as Chief Medical Officer, effective January 22, 2024. He will lead all clinical services, ensuring that LifeStance's psychiatric and psychotherapy clinicians are enabled to deliver high-quality, personalized patient care that meets and exceeds professional standards. "Dr. Ramtekkar is an experienced physician executive with a demonstrated track record of d

    $LFST
    Medical/Nursing Services
    Health Care
  • LifeStance Health Appoints J. Michael Bruff as New Business Transformation Officer; David Bourdon as Chief Financial Officer

    SCOTTSDALE, Ariz., Nov. 3, 2022 /PRNewswire/ --  LifeStance Health (NASDAQ:LFST), one of the nation's largest providers of outpatient mental healthcare, today announced that effective November 10, 2022, J. Michael Bruff, currently Chief Financial Officer, will take on a new role as Business Transformation Officer. David Bourdon will join the company and succeed Bruff as Chief Financial Officer. Both executives will report directly to Ken Burdick, Chairman and Chief Executive Officer, LifeStance. During LifeStance's long-range planning process, the company's leadership team ide

    $LFST
    Medical/Nursing Services
    Health Care

$LFST
Financials

Live finance-specific insights

See more
  • LifeStance Appoints Dave Bourdon as CEO; Ken Burdick Named Executive Chairman

    Ryan McGroarty to Become Chief Financial Officer SCOTTSDALE, Ariz., Feb. 27, 2025 /PRNewswire/ -- LifeStance Health Group, Inc. ("LifeStance" or the "Company") (NASDAQ:LFST), one of the nation's largest providers of outpatient mental health care, today announced that its Board of Directors has appointed Dave Bourdon as the Company's new Chief Executive Officer. Bourdon, who joined LifeStance as Chief Financial Officer in 2022, is succeeding Ken Burdick, who is retiring from his role as CEO and will assume the role of Executive Chairman. Bourdon has also been appointed to serve on the Board of Directors. In addition, Ryan McGroarty has been appointed to serve as the company's new Chief Financ

    $LFST
    Medical/Nursing Services
    Health Care
  • LifeStance to Host Fourth Quarter and Full Year 2024 Earnings Conference Call on February 27, 2025

    SCOTTSDALE, Ariz., Feb. 06, 2025 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ:LFST), one of the nation's largest providers of outpatient mental health care, will issue its fourth quarter and full year 2024 earnings release before the market opens on Thursday, February 27, 2025. LifeStance will host a live earnings conference call to discuss fourth quarter and full year results on February 27, 2025, at 8:30 a.m. Eastern Time. To participate in the call, please dial 1-800-715-9871, domestically, or 1-646-307-1963, internationally, and use conference ID 4372752, or ask to be joined into the LifeStance call. A real-time audio webcast can be accessed via the Events and Presentati

    $LFST
    Medical/Nursing Services
    Health Care
  • LifeStance to Host Third Quarter 2024 Earnings Conference Call on November 7, 2024

    SCOTTSDALE, Ariz., Oct. 17, 2024 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ:LFST), one of the nation's largest providers of outpatient mental health care, will issue its third quarter 2024 earnings release before the market opens on Thursday, November 7, 2024. LifeStance will host a live earnings conference call to discuss third quarter results on November 7, 2024, at 8:30 a.m. Eastern Time. To participate in the call, please dial 1-800-715-9871, domestically, or 1-646-307-1963, internationally, and use conference ID 2787723, or ask to be joined into the LifeStance call. A real-time audio webcast can be accessed via the Events and Presentations section of the LifeS

    $LFST
    Medical/Nursing Services
    Health Care

$LFST
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more